These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 37000221)

  • 1. The novel anti-cancer fluoropyrimidine NUC-3373 is a potent inhibitor of thymidylate synthase and an effective DNA-damaging agent.
    Bré J; Dickson AL; Read OJ; Zhang Y; McKissock FG; Mullen P; Tang P; Zickuhr GM; Czekster CM; Harrison DJ
    Cancer Chemother Pharmacol; 2023 May; 91(5):401-412. PubMed ID: 37000221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I open-label, dose-escalation study of NUC-3373, a targeted thymidylate synthase inhibitor, in patients with advanced cancer (NuTide:301).
    Spiliopoulou P; Kazmi F; Aroldi F; Holmes T; Thompson D; Griffiths L; Qi C; Parkes M; Lord S; Veal GJ; Harrison DJ; Coyle VM; Graham J; Jeffry Evans TR; Blagden SP
    J Exp Clin Cancer Res; 2024 Apr; 43(1):100. PubMed ID: 38566164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Limits to thymidylate synthase and TP53 genes as predictive determinants for fluoropyrimidine sensitivity and further evidence for RNA-based toxicity as a major influence.
    Brody JR; Hucl T; Costantino CL; Eshleman JR; Gallmeier E; Zhu H; van der Heijden MS; Winter JM; Wikiewicz AK; Yeo CJ; Kern SE
    Cancer Res; 2009 Feb; 69(3):984-91. PubMed ID: 19155291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined modulation by leucovorin and alpha-2a interferon of fluoropyrimidine mediated growth inhibition.
    Sinnige HA; Timmer-Bosscha H; Peters GF; De Vries EG; Mulder NH
    Anticancer Res; 1993; 13(5A):1335-40. PubMed ID: 8239504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of FdUMP[10] in treatment of HT-29 human colon cancer xenografts.
    Liu C; Willingham M; Liu J; Gmeiner WH
    Int J Oncol; 2002 Aug; 21(2):303-8. PubMed ID: 12118325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel polypyrimidine antitumor agent FdUMP[10] induces thymineless death with topoisomerase I-DNA complexes.
    Liao ZY; Sordet O; Zhang HL; Kohlhagen G; Antony S; Gmeiner WH; Pommier Y
    Cancer Res; 2005 Jun; 65(11):4844-51. PubMed ID: 15930305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased cytotoxicity and decreased in vivo toxicity of FdUMP[10] relative to 5-FU.
    Liu J; Skradis A; Kolar C; Kolath J; Anderson J; Lawson T; Talmadge J; Gmeiner WH
    Nucleosides Nucleotides; 1999 Aug; 18(8):1789-802. PubMed ID: 10478484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of 5-fluorodeoxyuridine monophosphate-thymidylate synthase ternary complex levels by autophagy confers resistance to 5-fluorouracil.
    Nishizawa N; Kurasaka C; Ogino Y; Sato A
    FASEB Bioadv; 2023 Jan; 5(1):43-51. PubMed ID: 36643896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors.
    Rustum YM; Harstrick A; Cao S; Vanhoefer U; Yin MB; Wilke H; Seeber S
    J Clin Oncol; 1997 Jan; 15(1):389-400. PubMed ID: 8996166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calpain regulates thymidylate synthase-5-fluoro-dUMP complex levels associated with response to 5-fluorouracil in gastric cancer cells.
    Nabeya Y; Suzuki T; Furuya A; Koide N; Ohkoshi M; Takiguchi M; Ochiai T; Matsubara H; Hiwasa T
    Cancer Sci; 2011 Aug; 102(8):1509-15. PubMed ID: 21561529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benzylacyclouridine enhances 5-fluorouracil cytotoxicity against human prostate cancer cell lines.
    Yee LK; Chu E; Pan BC; Chu SH; Chen TM; Lipsky MH; Chu MY; Calabresi P
    Pharmacology; 1998 Feb; 56(2):80-91. PubMed ID: 9494066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Positive interaction between 5-FU and FdUMP[10] in the inhibition of human colorectal tumor cell proliferation.
    Liu J; Kolath J; Anderson J; Kolar C; Lawson TA; Talmadge J; Gmeiner WH
    Antisense Nucleic Acid Drug Dev; 1999 Oct; 9(5):481-6. PubMed ID: 10555156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Time course of inhibition of thymidylate synthase in patients treated with fluorouracil and leucovorin.
    Peters GJ; van Groeningen CJ; van der Wilt CL; Meijer S; Smid K; Laurensse E; Pinedo HM
    Semin Oncol; 1992 Apr; 19(2 Suppl 3):26-35. PubMed ID: 1557655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Impact of Thymidylate Synthase and Methylenetetrahydrofolate Reductase Genotypes on Sensitivity to 5-Fluorouracil Treatment in Colorectal Cancer Cells.
    Naghibalhossaini F; Shefaghat M; Mansouri A; Jaberi H; Tatar M; Eftekhar E
    Acta Med Iran; 2017 Dec; 55(12):751-758. PubMed ID: 29373881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic exposure of colorectal cancer cells in culture to fluoropyrimidine analogs induces thymidylate synthase and suppresses p53. A molecular explanation for the mechanism of 5-FU resistance.
    Subbarayan PR; Sarkar M; Nelson G; Benitez E; Singhal S; Ardalan B
    Anticancer Res; 2010 Apr; 30(4):1149-56. PubMed ID: 20530421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unique dual targeting of thymidylate synthase and topoisomerase1 by FdUMP[10] results in high efficacy against AML and low toxicity.
    Pardee TS; Gomes E; Jennings-Gee J; Caudell D; Gmeiner WH
    Blood; 2012 Apr; 119(15):3561-70. PubMed ID: 22362039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic efficacy of 3n-butyrate and 5-fluorouracil in human colorectal cancer xenografts via modulation of DNA synthesis.
    Bras-Gonçalves RA; Pocard M; Formento JL; Poirson-Bichat F; De Pinieux G; Pandrea I; Arvelo F; Ronco G; Villa P; Coquelle A; Milano G; Lesuffleur T; Dutrillaux B; Poupon MF
    Gastroenterology; 2001 Mar; 120(4):874-88. PubMed ID: 11231942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dihydropyrimidine dehydrogenase but not thymidylate synthase expression is associated with resistance to 5-fluorouracil in colorectal cancer.
    Nita ME; Tominaga O; Nagawa H; Tsuruo T; Muto T
    Hepatogastroenterology; 1998; 45(24):2117-22. PubMed ID: 9951876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduction of 5-fluorouracil (5-FU) gastrointestinal (GI) toxicity resulting from the protection of thymidylate synthase (TS) in GI tissue by repeated simultaneous administration of potassium oxonate (Oxo) in rats.
    Yoshisue K; Hironaga K; Yamaguchi S; Yamamoto A; Nagayama S; Kawaguchi Y
    Cancer Chemother Pharmacol; 2000; 46(1):51-6. PubMed ID: 10912578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular Mechanisms and Tumor Biological Aspects of 5-Fluorouracil Resistance in HCT116 Human Colorectal Cancer Cells.
    Kurasaka C; Ogino Y; Sato A
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33805673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.